Recent Posts on This Topic | See All >
[Source: TGen] - Using computer modeling, the Translational Genomics Research Institute and Scottsdale Healthcare have discovered lung cancer ‘pathways’ that could become targets for new drugs, according to a scientific paper published online today by the Journal of Thoracic Oncology.
Dr. Glen Weiss, Director of Thoracic Oncology at TGen Clinical Research Services (TCRS) at Scottsdale Healthcare, said the study showed the value of conducting computer modeling, or “in silico” research.
TCRS is a partnership of TGen and Scottsdale Healthcare. The partnership allows molecular and genomic discoveries made by TGen and others around the world to reach the patient bedside in the Virginia G. Piper Cancer Center at Scottsdale Healthcare as quickly as possible through clinical trials with agents directed at specific cancer targets.
Researchers hope that over time in silico research will help lower health care costs while speeding up the process of turning scientific discoveries into treatments for patients.
For more information: TGen and Scottsdale Healthcare discover new ‘pathways’